Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns

Megan Hansen[1,2], Nadine M. Hamieh[1], Sarah C. Markt[3], Jane B. Vaselkiv[1], Claire H. Pernar[1], Amparo G. Gonzalez-Feliciano[1], Samuel Peisch[1], Ilkania M. Chowdhury-Paulino[1], Emily M. Rencsok[1,4], Timothy R. Rebbeck[1,5], Elizabeth A. Platz[6], Edward L. Giovannucci[1,7,8], Kathryn M. Wilson[1,7], and Lorelei A. Mucci[1,7]

ABSTRACT

Background: Racial disparities in prostate cancer incidence and mortality rates are considerable. We previously found in the Health Professionals Follow-up Study (HPFS) that African-American men had an 80% higher prostate cancer risk than White men. With 21 additional years of follow-up and four-fold increase in cases, we undertook a contemporary analysis of racial differences in prostate cancer incidence and mortality in HPFS.

Methods: For 47,679 men, we estimated HRs and 95% confidence intervals (CI) for the association between race and risk of prostate cancer through 2016 using Cox proportional hazards regression. Multivariable models (mHR) were adjusted for lifestyle, diet, family history, and PSA screening collected on biennial questionnaires.

Results: 6,909 prostate cancer cases were diagnosed in White, 89 in African-American, and 90 in Asian-American men. African-Americans had higher prostate cancer incidence (mHR = 1.31; 95% CI, 1.06–1.62) and mortality (mHR = 1.67; 95% CI, 1.00–2.78), and lower PSA screening prevalence than White men. The excess risk was greater in the pre-PSA screening era (HR = 1.68; 95% CI, 1.14–2.48) than the PSA screening era (HR = 1.20; 95% CI, 0.93–1.56). Asian-Americans had lower prostate cancer risk (mHR = 0.74; 95% CI, 0.60–0.92), but similar risk of fatal disease compared with white men.

Conclusions: Racial differences in prostate cancer incidence and mortality in HPFS are not fully explained by differences in lifestyle, diet, family history, or PSA screening.

Impact: Additional research is necessary to address the disproportionately higher rates of prostate cancer in African-American men.

Introduction

There are profound population-level racial disparities in prostate cancer incidence and mortality in the United States (1–8). African-American men are 76% more likely to be diagnosed with—and 120% more likely to die from—prostate cancer compared with White men (9). Conversely, Asian-American men are 55% less likely to be diagnosed with prostate cancer than White men, but in some studies, have a higher incidence of high-grade prostate cancer (1, 10, 11). Understanding these health disparities is important to inform both clinical practice and health policy.

The reasons for these considerable differences are not fully understood (4, 8, 12–17), although racial differences in lifestyle factors, access to care, screening, and inherited genetic factors have been suggested (3, 18–20). A prior analysis within the Health Professionals Follow-up Study (HPFS) through 1996 showed that, even after accounting for racial differences in epidemiologic factors, African-American men had an 81% higher incidence of prostate cancer compared with White men (4). We also noted differences by European ancestry, with highest risk in men who reported their ancestry as Scandinavian, a finding consistent with observed higher prostate cancer incidence and mortality in Scandinavian countries compared with other European countries (21).

With 21 additional years of follow-up, 5,096 additional prostate cancer cases to study clinical subtypes, e.g., fatal, lethal, advanced, and high-grade disease, and changing patterns of screening, we provide a contemporary analysis in HPFS to assess whether racial and ancestry differences in prostate cancer incidence and mortality remain after accounting for differences in lifestyle, family history, and PSA screening history.

Materials and Methods

The prospective HPFS cohort includes 51,529 male health professionals aged 40 to 75 years at baseline in 1986 when men completed a baseline questionnaire regarding demographics, medical history, family history, and lifestyle. They have been followed via questionnaires (22) every 2 years to update medical history, lifestyle, and PSA-based prostate cancer screening history (starting in 1994), and every 4 years to update diet. We excluded men who were diagnosed with prostate cancer prior to baseline ($n = 328$), died before 1986 ($n = 12$), or were missing diagnosis date ($n = 21$) or birthdate ($n = 34$). Men were also excluded if they did not report their major ancestry ($n = 2{,}591$) or selected "other ancestry" ($n = 864$). 47,679 men were

[1]Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. [2]UMass Chan Medical School, University of Massachusetts, Worcester, Massachusetts. [3]Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio. [4]Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts. [5]Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. [6]Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. [7]Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts. [8]Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

M. Hansen and N.M. Hamieh contributed equally to this article.

Corresponding Author: Lorelei A. Mucci, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115. Phone: 617-432-1732; E-mail: lmucci@hsph.harvard.edu

Cancer Epidemiol Biomarkers Prev 2022;31:982–90

doi: 10.1158/1055-9965.EPI-21-1064

followed prospectively for cancer incidence through January 2017 and mortality through January 2019 (**Fig. 1**).

The Institutional Review Board of Harvard T.H. Chan School of Public Health (Boston, MA) approved the HPFS.

Self-reported ancestry

Participants self-reported their major ancestry(ies) at baseline with the option to choose one or more of the following categories: Asian-American, African-American, Scandinavian, Southern European, other European, or other origin. For men reporting multiple ancestries, we classified for this analysis those reporting White and African-American ($n = 35$) as African-American, and as White and Asian-American ($n = 28$) as Asian-American. The 864 men who reported "other origin" were excluded from this analysis.

Prostate cancer incidence and mortality

Incident prostate cancer was identified by self-report and confirmed through standardized review of medical records (23). Gleason score at biopsy and prostatectomy (if surgically treated), tumor stage, and PSA at diagnosis were extracted from medical records. Gleason score was available from a centralized histopathologic rereview of hematoxylin and eosin slides for one-third of prostate cancer cases (24). Prostate cancer–specific mailed questionnaires collect updated information on treatment, disease recurrence, and metastasis. HPFS is followed for death through reports by next-of-kin and linkage with the National Death Index. Cause of death, including for prostate cancer, is adjudicated by the Endpoints Committee. Follow-up for cancer incidence is 96% and for mortality is more than 99%.

The main outcomes for this analysis were incident prostate cancer, defined as first primary prostate cancer diagnosis, and fatal prostate cancer, defined as a death from prostate cancer as the underlying cause. We also investigated lethal prostate cancer, defined as distant metastases or death from prostate cancer; advanced disease defined as lethal or stages T3b, T4, N1, or M1 at diagnosis; and high-grade prostate cancer defined as Gleason score of 4 + 3 and above. Men with missing data on stage or grade were only included in the analyses of overall and fatal prostate cancer.

Statistical analysis

Statistical analyses were undertaken using SAS version 9.4 (25). *P* values were two-sided with statistical significance set at $P < 0.05$. Each participant contributed person-time from the return date of the baseline questionnaire until prostate cancer diagnosis, death, or end of the study. Participants were followed until January 2017 for cancer incidence and until January 2019 for cancer mortality. For analyses of clinical subtypes, e.g., with advanced or high-grade prostate cancer as the endpoint, men with localized prostate cancer were censored at date of diagnosis as a competing risk.

Age-standardized baseline descriptive characteristics by race/ancestry were computed. Cox proportional hazards models with age as the time scale and stratified by calendar time were used to estimate HRs and 95% confidence intervals (CI) for the associations of race/ancestry with prostate cancer endpoints. These models are equivalent to the population-level assessment of potential differences in prostate cancer rates by race/ancestry in HPFS.

Multivariable models were adjusted for prostate cancer risk factors: height (≤68, >68–70, >70–72, >72 inches), body mass index (BMI; <21, 21 to <25, 25 to <30, ≥30 kg/m^2), cigarette smoking (never, former smoker who quit >10 years ago, former smoker who quit ≤10 years ago, current smoker), vigorous physical activity [quartiles of metabolic equivalent (MET) hours/week], family history of prostate cancer in father or brother, recent PSA screening (PSA testing in the 2 years prior to the questionnaire date, lagged by one questionnaire to avoid diagnostic screening), history of PSA screening (PSA testing in >50% of possible time periods, also lagged by one questionnaire period), and dietary factors: total energy (quartiles, kcal/day), tomato sauce (quartiles, servings/week), calcium from diet and supplements (quartiles, mg/day), and coffee (none, <1, 1 to <2, 2 to <3, ≥3 cups/day). Time-varying variables were updated based on biennial questionnaires. Multivariable models provide an assessment of the extent to which racial/ancestry differences in prostate cancer incidence and mortality at the population level can be explained by racial/ancestry differences in lifestyle, family history, and screening.

Given the potential influence of PSA screening, including racial/ancestry differences in PSA screening history, we stratified analyses by the pre-PSA (1986–1994) and the PSA (1994–2016) eras.



Figure 1.
Exclusions to create the final study population within the HPFS.

Data availability

The data generated in this study are available upon request from the corresponding author.

Results

At baseline, 46,281 men reported their ancestry as White, 523 as African-American, 875 as Asian-American, and 864 as other ancestry. Among White men, 12,080 reported their ancestry as Southern European, 5,195 Scandinavian, and 29,006 other European ancestry. **Table 1A** provides a comparison of baseline lifestyle factors, diet, and screening patterns in men across races/ancestry. African-American men had higher vigorous physical activity but were more likely to be current or recent former smokers than White men. Asian-American men were of shorter height on average, were less likely to be overweight, and had a lower prevalence of prostate cancer family history compared with their White and African-American counterparts. White men reported higher intakes of energy, tomato sauce, coffee, and total calcium than African-American and Asian-American men. Compared with Southern European men, Scandinavian men were slightly taller and somewhat less likely to engage in vigorous physical activity. Asian-American men also had a substantially higher mean PSA at time of diagnosis (26.3 ng/mL) compared with both African-American (13.9 ng/mL) and White men (17.8 ng/mL; **Table 1B**).

During follow-up (1,100,482 person-years), 7,088 men were diagnosed with prostate cancer: 6,909 White, 89 African-American, and 90 Asian-American translating to crude incidence rates (per 100,000 person-years) of 647, 785, and 410, respectively. Of the cancers, there were 910 fatal, 1,094 lethal, 1,337 advanced, and 1,605 high-grade. The corresponding prostate cancer mortality rates were 82 (White), 141 (African-American), and 68 (Asian-American) per 100,000 person years. Adjusting for age and calendar time, African-American men had a higher prostate cancer incidence (HR = 1.21; 95% CI, 0.98–1.49) compared with White men, whereas Asian-American men had a lower incidence (HR = 0.67; 95% CI, 0.54–0.82). These differences were essentially unchanged after accounting for racial differences in epidemiologic factors, with African-American men having 31% higher (HR = 1.31; 95% CI, 1.06–1.62) incidence and Asian-American men having a 26% lower (HR = 0.74; 95% CI, 0.60–0.92) incidence compared with White men.

The risk of clinically significant cancers also differed. African-American men had a higher incidence of fatal, lethal, and advanced (but not high-grade) prostate cancers compared to white men in both age- and multivariable-adjusted models. There were no statistically significant relative risk estimates for clinically significant cancers among Asian-American men, although there was a suggestion of increased risk of high-grade cancer in both age- and multivariable-adjusted models compared with White men.

Among White men, 1,677 prostate cancer cases were diagnosed in Southern Europeans, 777 in Scandinavians, and 4,455 in men of other European ancestry, translating to incidence rates (per 100,000 person-years) of 591, 638, and 674, respectively. Scandinavian men and men of other European ancestry had a slightly higher prostate cancer incidence and mortality compared with Southern European men; however, this difference was nonsignificant after multivariable adjustment (**Table 2**).

In age- and multivariable-adjusted models, the higher prostate cancer risk in African-American compared with White men was greater in the pre-PSA than in the PSA era, while the lower prostate cancer risk in Asian-American men was slightly augmented in the PSA era. Among White men, the higher prostate cancer risk in men of Scandinavian and other European ancestry compared with men with Southern European ancestry was similar in the pre-PSA and PSA eras (**Table 3**).

Figure 2 shows the percent of men who underwent PSA screening in each 2-year questionnaire period by race. There was substantial variation in the proportion of African-American, White, and Asian-American men who had a PSA test over time. While each group exhibited similar patterns—a rise from 1994 to 2000, followed by a steady decline—there were also differences in the proportion of each group screened: White men were most likely to be screened, while

Table 1A. Age-adjusted characteristics of baseline population by race and European ancestry, HPFS 1986 (n = 47,679).

			European-American			
	African-American	Asian-American	All White	Southern European	Scandinavian	Other European
n	523	875	46,281	12,080	5,195	29,006
Mean age, years (SD)[a]	54.6 (8.9)	52.3 (9.0)	54.2 (9.8)	53.6 (9.7)	53.4 (9.7)	54.7 (9.9)
Mean height, inches (SD)	70.1 (3.4)	67.0 (3.1)	70.2 (2.8)	69.7 (2.9)	70.7 (2.8)	70.2 (2.8)
Mean BMI at age 21 years, kg/m^2 (SD)	22.8 (3.6)	21.9 (3.2)	23.0 (3.0)	23.2 (3.1)	23.0 (2.9)	23.0 (3.0)
Mean current BMI, kg/m^2 (SD)	26.0 (3.8)	24.2 (3.4)	25.5 (3.3)	25.7 (3.3)	25.5 (3.4)	25.5 (3.3)
Smoking status						
Never smoker, %	41.1	52.8	46.0	46.0	47.9	45.6
Past smoker quit >10 years, %	28.9	25.4	30.7	31.0	30.0	30.7
Past smoker quit ≤10 years, %	14.2	11.4	12.9	12.9	11.9	13.0
Current smoker, %	14.5	9.2	9.9	9.4	9.5	10.1
Unknown, %	1.2	1.2	0.6	0.7	0.7	0.6
History of diabetes, %	7.1	6.2	3.1	3.2	2.7	3.1
Family history of prostate cancer, %	12.2	7.2	12.0	11.5	13.3	12.0
PSA screening history						
Ever had a PSA test by 1994, %	31.1	32.2	46.5	46.3	44.0	47.0
Ever had a PSA test by 1996, %	46.2	46.8	60.8	60.6	57.8	61.3
Ever had a PSA test by 2016, %	73.4	75.8	84.0	83.4	83.4	84.2
PSA screening in last 2 years, 2016, %	17.3	20.8	27.4	27.6	26.0	27.4
Mean vigorous activity METs/week (SD)	8.1 (32.2)	6.1 (15.9)	6.0 (19.5)	6.2 (22.0)	5.7 (20.5)	5.9 (18.4)
Mean total energy intake kcal/day (SD)	1854 (654)	1844 (648)	1994 (609)	1951 (608)	2066 (614)	1998 (608)
Mean coffee, cups/day (SD)	0.9 (1.1)	1.5 (1.5)	1.9 (1.8)	1.9 (1.7)	2.0 (1.9)	2.0 (1.8)
Mean tomato sauce, servings/week (SD)	0.7 (1.4)	0.8 (1.1)	0.9 (1.1)	1.1 (1.3)	0.9 (1.0)	0.9 (1.1)
Mean calcium, mg/day (SD)	760 (407)	731 (365)	901 (421)	870 (412)	972 (443)	902 (419)

[a]Value is not age-adjusted.

Table 1B. Age-adjusted clinical characteristics of prostate cancer cases at the time of diagnosis, by race and European ancestry, HPFS ($n = 7{,}088$).

			European-American			
	African-American	Asian-American	All White	Southern European	Scandinavian	Other European
n	89	90	6,909	1,677	777	4,455
Year of diagnosis						
1986–1989, %	4.2	3.4	4.9	4.5	5.5	4.9
1990–1994, %	30.2	18.9	19.1	18.4	18.9	19.3
1995–1999, %	20.0	20.2	21.7	21.8	22.0	21.6
2000–2004, %	24.4	23.1	22.7	23.0	22.0	22.7
2005–2009, %	13.8	20.6	19.7	19.2	19.1	19.9
2010–2014, %	5.3	11.8	10.0	10.6	10.4	9.6
2015–2016, %	2.2	2.0	2.0	2.4	2.1	1.9
Mean age at diagnosis, years (SD)[a]	70.3 (6.7)	70.7 (7.0)	70.1 (7.5)	69.8 (7.5)	69.2 (7.4)	70.4 (7.4)
Mean PSA at diagnosis, ng/mL (SD)	13.9 (17.7)	26.3 (99.8)	17.8 (152.3)	15.3 (141.2)	30.7 (269.0)	16.5 (127.0)
Primary treatment						
Radical prostatectomy, %	32.9	29.6	38.1	37.8	41.0	37.8
Radiation, %	23.4	31.3	30.9	30.5	29.0	31.3
Hormones, %	5.3	8.8	6.8	6.1	7.0	7.1
Active surveillance/no treatment, %	14.9	10.5	9.3	10.1	8.2	9.2
Other treatment, %	1.0	0	1.9	1.8	1.9	1.8
Unknown treatment, %	22.4	19.9	13.0	13.7	12.9	12.7
TNM stage[b]						
T1/T2, %	86.9	80.0	82.9	84.4	81.2	82.7
T3a, %	1.3	8.5	8.1	7.7	7.3	8.4
T3b, %	2.6	1.6	3.1	2.8	4.2	3.1
T4/N1/M1, %	9.2	9.9	5.9	5.2	7.1	5.9
Missing TNM stage, %	20.3	18.6	10.5	12.5	10.1	9.8
Gleason grade[c]						
Gleason 2–6, %	44.8	31.1	47.3	47.9	47.4	47.0
Gleason 7, 3 + 4%	26.8	24.2	22.9	22.8	22.4	23.1
Gleason 7, 4 + 3%	7.1	14.2	11.1	10.5	11.2	11.3
Gleason 7 (breakdown unknown), %	8.4	4.1	3.2	3.6	4.1	3.0
Gleason 8–10, %	12.9	26.3	15.5	15.2	14.8	15.7
Missing Gleason grade, %	26.5	21.2	15.0	16.8	15.1	14.3

Note: Values are means (SD) and percentages for categorical variables are standardized to the age distribution of the study population.
Abbreviation: TNM, tumor–node–metastasis.
[a]Value is not age-adjusted.
[b]Combined clinical and pathologic stage (clinical stage used only if pathologic stage was unavailable).
[c]Combined clinical and pathologic Gleason (clinical Gleason used only if pathologic Gleason was unavailable).

African-American men were the least likely. **Figure 3** shows trends over time in aggregate prostate cancer screening in our study cohort, demonstrating that there is a steady rise followed by a plateau in men who reported ever having received a PSA test; rates continue to be higher in White men compared with both Asian-American and African-American men.

Discussion

In this large prospective cohort with 30 years of follow-up, we observed a higher prostate cancer incidence and mortality in African-American men and a lower incidence in Asian-American men. These differences were not explained by differences in lifestyle, diet, family history, or PSA screening. The higher risk of overall prostate cancer in African-American men was seen despite lower PSA screening uptake, a key determinant of prostate cancer incidence in the population.

That the higher risk in African-American men was only minimally attenuated by multivariable adjustment suggests that differences in the prevalence of known lifestyle and dietary factors measured in this study has only a small contribution to this excess incidence. This is consistent with prior studies suggesting that disparities remain after controlling for many of the factors long thought to contribute to these differences (20, 26, 27). Notably, our cohort of health professionals is a unique population in which to examine this question among men with similarly high educational attainment and midlife socioeconomic status. The 31% higher risk of prostate cancer in HPFS for African-American men compared with White men is lower than population estimates which, from 2011 to 2015, showed African-American men were 76% more likely to be diagnosed with prostate cancer than White men (9). This difference may reflect a role for adult socioeconomic status or could indicate differences in PSA screening with the aging of the population.

Nationally, the age-adjusted prostate cancer mortality rate in African-American men is 2.3 times higher than in White men (9). In the HPFS, we observed a 67% higher risk of fatal prostate cancer in African-American men compared with White men after multivariable adjustment, though this estimate had wide CIs. Despite attenuation of this mortality difference in our population, the remaining disparity is concerning, especially considering that other noncancer causes of mortality are not substantially increased in African-American men in HPFS (28). While socioeconomic status may play a role in attenuating disparate outcomes in prostate cancer mortality (26), the large

Table 2. Incidence rates and HRs and 95% CIs for the association between race/ancestry and prostate cancer risk in the HPFS cohort, 1986–2017.

			HR (95% CI)	
	Cases (*n*)	Crude incidence/ 100,000 PY	Age/calendar time-adjusted	Multivariable-adjusted[a]
All prostate cancer	7,088	644		
Race				
White	6,909	647	ref	1.00 (ref)
African-American	89	785	1.21 (0.98–1.49)	1.31 (1.06–1.62)
Asian-American	90	410	0.67 (0.54–0.82)	0.74 (0.60–0.92)
European ancestry				
Southern European	1,677	591	ref	1.00 (ref)
Scandinavian	777	638	1.10 (1.01–1.20)	1.07 (0.98–1.17)
Other European	4,455	674	1.09 (1.03–1.16)	1.07 (1.01–1.14)
Fatal cancer	910	83		
Race				
White	879	82	ref	1.00 (ref)
African-American	16	141	1.74 (1.05–2.87)	1.67 (1.00–2.78)
Asian-American	15	68	1.07 (0.64–1.80)	1.25 (0.74–2.11)
European ancestry				
Southern European	194	68	ref	1.00 (ref)
Scandinavian	98	80	1.20 (0.94–1.53)	1.10 (0.86–1.42)
Other European	587	89	1.17 (0.99–1.37)	1.13 (0.95–1.33)
Lethal cancer	1,094	99		
Race				
White	1,059	99	ref	1.00 (ref)
African-American	16	141	1.41 (0.86–2.33)	1.36 (0.82–2.25)
Asian-American	19	87	1.10 (0.70–1.75)	1.24 (0.78–1.98)
European ancestry				
Southern European	231	81	ref	1.00 (ref)
Scandinavian	126	103	1.29 (1.04–1.61)	1.21 (0.97–1.52)
Other European	702	106	1.17 (1.01–.37)	1.14 (0.98–1.33)
Advanced cancer	1,337	121		
Race				
White	1,297	122	ref	1.00 (ref)
African-American	20	177	1.42 (0.91–2.22)	1.39 (0.88–2.18)
Asian-American	20	91	0.91 (0.59–1.43)	1.04 (0.66–1.63)
European ancestry				
Southern European	291	102	ref	1.00 (ref)
Scandinavian	156	128	1.27 (1.04–1.54)	1.18 (0.97–1.44)
Other European	850	129	1.14 (1.00–1.31)	1.11 (0.97–1.27)
High-grade cancer, Gleason 4 + 3 or higher	1,605	146		
Race				
White	1,562	146	ref	1.00 (ref)
African-American	14	124	0.82 (0.48–1.39)	0.89 (0.52–1.51)
Asian-American	29	132	0.97 (0.67–1.41)	1.14 (0.78–1.67)
European ancestry				
Southern European	357	126	ref	1.00 (ref)
Scandinavian	172	141	1.14 (0.95–1.37)	1.06 (0.88–1.27)
Other European	1,033	156	1.20 (1.06–1.35)	1.15 (1.01–1.29)

Abbreviation: PY: person years.

[a]Models adjusted for age, calendar time, height (≤68, >68–70, >70–72, >72 inches), BMI (<21, 21 to <25, 25 to <30, 30+ kg/m^2), vigorous physical activity (MET-hours/week, quartiles), smoking status (never, former/quit <10 years ago, former/quit 10+ years ago, or current), time-updating family history of prostate cancer, PSA testing in the 2 years prior to the questionnaire date (lagged by one period to avoid counting diagnostic PSA tests as screening), PSA testing in >50% of possible time periods (lagged by one period), total energy intake (kcal/day, quartiles), coffee intake (none, <1, 1 to <2, 2 to <3, 3+ cups/day), tomato sauce intake (servings/week, quartiles), and calcium intake (mg/day, quartiles).

remaining racial difference in our cohort of men with uniformly high educational attainment disputes this as the only explanation, and its lack of attenuation after multivariable adjustment argues against a significant role for lifestyle factors.

A crucial missing piece not accounted for in our study is an investigation of systemic inequities in healthcare access and quality. There are profound differences in prostate cancer treatment between African-American and White men. For example, one study showed that a lower proportion of African-American men were offered radical prostatectomy compared with White men (29) and indeed, in our study, both African-American and Asian-American men were less likely to receive radical prostatectomy. Notably, overtreatment of

Table 3. Incidence rates and HRs and 95% CIs for the association between race/ancestry and incident prostate cancer in HPFS cohort by pre-PSA era and PSA era.

			HR (95% CI)	
	Cases (*n*)	**Crude incidence/ 100,000 PY**	**Age/calendar time-adjusted**	**Multivariable-adjusted[a]**
Pre-PSA era (1986–1994)	1,556	134		
Race				
White	1,511	134	ref	1.00 (ref)
African-American	28	234	1.63 (1.11–2.39)	1.68 (1.14–2.48)
Asian-American	17	75	0.76 (0.47–1.22)	0.86 (0.53–1.39)
European ancestry				
Southern European	353	118	ref	1.00 (ref)
Scandinavian	175	136	1.19 (0.99–1.43)	1.11 (0.92–1.34)
Other European	983	141	1.02 (0.90–1.16)	0.97 (0.86–1.10)
PSA era (1994–2016)	5,532	743		
Race				
White	5,398	748	ref	1.00 (ref)
African-American	61	817	1.08 (0.84–1.40)	1.20 (0.93–1.56)
Asian-American	73	476	0.65 (0.51–0.82)	0.72 (0.57–0.92)
European ancestry				
Southern European	1,324	684	ref	1.00 (ref)
Scandinavian	602	726	1.07 (0.97–1.18)	1.06 (0.96–1.17)
Other European	3,472	780	1.12 (1.05–1.19)	1.10 (1.03–1.17)

Abbreviation: PY: person-years.

[a]Models adjusted for age, calendar time, height (≤68, >68–70, >70–72, >72 inches), BMI (<21, 21 to <25, 25 to <30, 30+ kg/m^2), vigorous physical activity (MET-hours/week, quartiles), smoking status (never, former/quit <10 years ago, former/quit 10+ years ago, or current), time-updating family history of prostate cancer, PSA testing in the 2 years prior to the questionnaire date (lagged by one period to avoid counting diagnostic PSA tests as screening-excluded from pre-PSA model), PSA testing in >50% of possible time periods (lagged by one period-excluded from pre-PSA model), total energy intake (kcals/day, quartiles), coffee intake (none, <1, 1 to <2, 2 to <3, 3+ cups/day), tomato sauce intake (servings/week, quartiles), and calcium intake (mg/day, quartiles).



Figure 2.
Trends over time in prevalence of recent PSA screening (in the past 2 years) among White, African-American, and Asian-American men, HPFS (N = 48,074).



Figure 3.
Trends over time in prevalence of men with any PSA screening history in White, African-American, and Asian-American men, HPFS ($N = 48{,}074$).

prostate cancer is persistent across race groups; however, one study demonstrated that in groups with highest potential treatment benefit, African-American men were significantly less likely to receive treatment compared with White men (30). Furthermore, chronic exposure to racism as a form of psychosocial stress is associated with changes in immune and endocrine function (31), while molecular mechanisms for the relationship between chronic stress and cancer have also been elucidated (32). Several studies have even directly linked residential segregation with cancer disparities (33–35)—including prostate cancer (36)—in African-Americans. While we are not able to control for these factors in the present study, further work should continue to explore the complex interactions between patients and their social environments.

There was lower PSA screening in African-American compared with White men in HPFS throughout the study period. It follows that when they are diagnosed, it is more likely to be with aggressive prostate cancer (37). While racial differences in screening patterns have been previously reported (38), it is notable that these differences persist in the setting of higher socioeconomic status. Given these differences, we assessed the impact of the introduction of PSA screening on the racial difference in prostate cancer risk and noted an attenuation of the racial disparity in the PSA era. However, it is important to note here that we were unable to parse risk of aggressive cancer by pre-PSA versus PSA era due to small sample sizes. It is likely that the increase in screening leads to an increase in diagnosis of indolent cancers across race groups—a well-documented effect of PSA screening (39, 40)—thereby diluting the difference in the PSA era.

Among men of White ancestry, our results show a modest increase in risk of total and advanced prostate cancer in Scandinavian compared with Southern European men; however, this result was nonsignificant after multivariable adjustment. This is comparable with prior studies of men of European ancestry living in the United States (41) and with international cancer statistics (21, 41). Previous data in our cohort showed that Scandinavian men consume more dairy and calcium (4) (associated with increased risk of total and aggressive prostate cancer; ref. 42) while Southern European men consume more tomato sauce (ref. 4 associated with decreased risk; ref. 42), which may partially explain the attenuation after multivariable adjustment.

In contrast, Asian-American men had a lower overall incidence of prostate cancer compared with White men; however, while nonsignificant, there was a suggestion of increased risk of high-grade cancer. This is consistent with current literature suggesting that tumor grade is higher in Asian-American men at time of diagnosis (43). This may be due in part to lower screening prevalence observed in our cohort. Importantly, as with all race groups, Asian-Americans are a vastly diverse cohort, and our inability to characterize risk by specific subtype is a limitation of this study.

Other limitations of the present study are the small number of African-American and Asian-American men and events in these groups; as such, our estimates for fatal, lethal, and advanced disease have wide confidence intervals. Still, we observed statistically significant findings and clinically meaningful effect estimates. Our study lacked data on Hispanic ethnicity or specific ancestries in Asian-American men. Very few in our cohort born from 1911 to 1946 self-identified

more than one race, so we are unable to comment on risk in multiracial persons. Although we adjusted for family history, we did not consider inherited genetic factors to explain differences in risk across groups. This is important since the distribution of a multiethnic polygenic risk score is higher in men of African ancestry (46). Furthermore, while this is a longitudinal cohort, this study only accounts for adult modifiable factors and does not consider early life exposures or social factors which may have substantial differences across race groups. In addition, while this cohort of health professionals allows us to control for adult socioeconomic status, results may not be generalizable to the entire population. Finally, these data deal with self-reported race and ethnicity as these are socially constructed. While there is a correlation between self-reported race and ancestry, we cannot draw conclusions about underlying genetic risk due to ancestry, which should be a focus of future investigations.

Notable strengths of our study include its prospective design, use of validated prostate cancer cases, and extensive nature of the biennial questionnaires, which allowed us to finely adjust for PSA testing and a range of lifestyle factors. Still, given the strong impact of PSA screening on prostate cancer diagnosis, there is the possibility that residual differences might be explained by screening. The long-term follow-up of the cohort over the course of three decades allows an investigation of prostate cancer risk across the lifespan. Finally, we were able to investigate not only prostate cancer overall, but clinically relevant and fatal disease.

In summary, our updated analysis of the HPFS demonstrates that African-American men have persistent, disproportionately higher rates of prostate cancer incidence and mortality that are not explained by differences in lifestyle factors, family history of prostate cancer, or PSA testing. Conversely, we found that Asian-American men have a lower risk of overall prostate cancer. While biological differences may partly account for the racial disparities in prostate cancer incidence, ultimately, race is socially constructed, and etiology of disparities in prostate cancer aggressiveness and mortality are likely multifactorial, including the socioeconomic and nonsocioeconomic facets of healthcare access, treatment, and outcomes.

Authors' Disclosures

I.M. Chowdhury-Paulino reports grants from T32 CA 009001 during the conduct of the study. E.A. Platz reports grants from NCI during the conduct of the study; in addition, E.A. Platz is the editor in chief of *Cancer Epidemiology, Biomarkers & Prevention* (*CEBP*); and has no bearing on the research conducted. L.A. Mucci reports grants from NCI Prostate Cancer Foundation during the conduct of the study; grants from AstraZeneca, Janssen; personal fees from Bayer HealthCare; and personal fees from Convergent Therapeutics outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions

M. Hansen: Visualization, writing–original draft. **N.M. Hamieh:** Writing–original draft. **S.C. Markt:** Writing–review and editing. **J.B. Vaselkiv:** Data curation, formal analysis, validation, writing–review and editing. **C.H. Pernar:** Writing–review and editing. **A.G. Gonzalez-Feliciano:** Formal analysis. **S. Peisch:** Project administration. **I.M. Chowdhury-Paulino:** Writing–review and editing. **E.M. Rencsok:** Writing–review and editing. **T.R. Rebbeck:** Writing–review and editing. **E.A. Platz:** Writing–review and editing. **E.L. Giovannucci:** Writing–review and editing. **K.M. Wilson:** Writing–review and editing. **L.A. Mucci:** Conceptualization, funding acquisition, methodology, writing–review and editing.

Acknowledgments

This project was supported by Prostate Cancer Foundation, the A. David Mazzone Research Awards Program of the Dana-Farber/Harvard Cancer Center, and the NCI (U01 167552). This project was a cross–cancer center collaboration between the Dana-Farber/Harvard Cancer Center [principal investigator (PI): Laurie Glimcher; P30 CA06516], Case Western University (Cleveland, OH; PI: Jonathan Karn; P30 CA043703), and the Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins University, Baltimore, MD; PI: William Nelson; P30 CA006973). We would like to thank the participants and staff of the HPFS for their valuable contributions. In particular, we are grateful for the contributions of Eleni Konstandis, Ruifeng Li, Betsy-Frost Hawes, Ann Fisher, and Siobhan Saint-Surin. We are grateful to the following U.S. state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The Editor-in-Chief of *Cancer Epidemiology, Biomarkers & Prevention* is an author on this article. In keeping with AACR editorial policy, a senior member of the *Cancer Epidemiology, Biomarkers & Prevention* editorial team managed the consideration process for this submission and independently rendered the final decision concerning acceptability.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 8, 2021; revised November 9, 2021; accepted February 22, 2022; published first March 3, 2022.

References

1. Kinseth MA, Jia Z, Rahmatpanah F, Sawyers A, Sutton M, Wang-Rodriguez J, et al. Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int J Cancer 2014;134:81–91.
2. Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of obesity with tumor characteristics and treatment failure of prostate cancer in african-american and european american men. J Urol 2007;178:1939–45.
3. Sanderson M, Coker AL, Logan P, Zheng W, Fadden MK. Lifestyle and prostate cancer among older African-American and Caucasian men in South Carolina. Cancer Causes Control 2004;15:647–55.
4. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92:2009–17.
5. Oren O, Oren M, Beach D. On the generalizability of prostate cancer studies: why race matters. Ann Oncol 2016;27:2146–8.
6. Kheirandish P, Chinegwundoh F. Ethnic differences in prostate cancer. Br J Cancer 2011;105:481–5.
7. Sartor O. Risk factors for prostate cancer [monograph on the internet]. Vogelzang N, Lee WR, Richie JP, Savarese DMF, editors. Waltham: UpToDate; 2022.
8. Ross RK, Shimizu H, Paganini-Hill A, Honda G, Henderson BE. Case-control studies of prostate cancer in blacks and whites in southern California. J Natl Cancer Inst 1987;78:869–74.
9. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin 2019;69:211–33.
10. Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995–2004. Cancer 2007;110:1255–63.
11. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of prostate cancer on autopsy: Cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013;105:1050–8.
12. Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, et al. ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate 2015;75:1677–81.
13. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends - an update. Cancer Epidemiol Biomarkers Prev 2016;25:16–27.
14. Hsing AW, Sakoda LC, Chua S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86:843–57.
15. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007;109:875–81.

16. Tantamango-Bartley Y, Knutsen SF, Knutsen R, Jacobsen BK, Fan J, Lawrence Beeson W, et al. Are strict vegetarians protected against prostate cancer? Am J Clin Nutr 2016;103:153–60.
17. Maurice MJ, Sundi D, Schaeffer EM, Abouassaly R. Risk of pathological upgrading and up staging among men with low risk prostate cancer varies by race: results from the national cancer database. J Urol 2017;197:627–31.
18. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39:638–44.
19. Eeles RA, Al Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45:385–91.
20. Graham-Steed T, Uchio E, Wells CK, Aslan M, Ko J, Concato J. "Race" and prostate cancer mortality in equal-access healthcare systems. Am J Med 2013; 126:1084–8.
21. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
22. Kenfield SA, Batista JL, Jahn JL, Downer MK, Van Blarigan EL, Sesso HD, et al. Development and application of a lifestyle score for prevention of lethal prostate cancer. J Natl Cancer Inst 2016;108:djv329.
23. Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, Van Dam RM, Stampfer MJ, et al. Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst 2011;103:876–84.
24. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009;27: 3459–64.
25. SAS Institute. SAS version 9.4. Cary, NC: SAS Inst Inc.; 2012.
26. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019;5:975–83.
27. Alexander M, Zhu K, Cullen J, Byrne C, Brown D, Shao S, et al. Race and overall survival in men diagnosed with prostate cancer in the department of defense military health system, 1990–2010. Cancer Causes Control 2019;30:627–35.
28. Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and vitamin d in black and white male health professionals. Cancer Epidemiol Biomarkers Prev 2006;15:2467–72.
29. Lediju O, Ikuemonisan J, Salami SS, Adejoro O. Racial disparities in the presentation, early definitive surgical treatment, and mortality among men diagnosed with poorly differentiated/undifferentiated non-metastatic prostate cancer in the USA. J Racial Ethn Heal Disparities 2019;6:401–8.
30. Presley CJ, Raldow AC, Cramer LD, Soulos PR, Long JB, Yu JB, et al. A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol 2013;4:1–8.
31. Ellison GL, Coker AL, Hebert JR, Sanderson M, Royal CD, Weinrich SP. Psychosocial stress and prostate cancer: A theoretical model. Ethn Dis 2001; 11:484–95.
32. Dai S, Mo Y, Wang Y, Xiang B, Liao Q, Zhou M, et al. Chronic stress promotes cancer development. Front Oncol 2020;10:1492.
33. Blanco BA, Poulson M, Kenzik KM, McAneny DB, Tseng JF, Sachs TE. The impact of residential segregation on pancreatic cancer diagnosis, treatment, and mortality. Ann Surg Oncol 2021;28:3147–55.
34. Poulson MR, Beaulieu-Jones BR, Kenzik KM, Dechert TA, Ko NY, Sachs TE, et al. Residential racial segregation and disparities in breast cancer presentation, treatment, and survival. Ann Surg 2021;273:3–9.
35. Poulson M, Cornell E, Madiedo A, Kenzik K, Allee L, Dechert T, et al. The impact of racial residential segregation on colorectal cancer outcomes and treatment. Ann Surg 2021;273:1023–30.
36. Poulson MR, Helrich SA, Kenzik KM, Dechert TA, Sachs TE, Katz MH. The impact of racial residential segregation on prostate cancer diagnosis and treatment. BJU Int 2021;127:636–44.
37. Naik G, Akinyemiju T. Disparities in hospitalization outcomes among African-American and White prostate cancer patients. Cancer Epidemiol 2017;46:73–9.
38. Jindal T, Kachroo N, Sammon J, Dalela D, Sood A, Vetterlein MW, et al. Racial differences in prostate-specific antigen – based prostate cancer screening : State-by-state and region-by-region analyses. Urol Oncol Semin Orig Investig 2017;35: 460.e9–460.e20.
39. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009;101:1325–9.
40. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
41. Gunderson K, Wang CY, Wang R. Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans. Cancer Epidemiol 2011;35:320–7.
42. Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998;58:442–7.
43. Raymundo EM, Rice KR, Chen Y, Zhao J, Brassell SA. Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system. BJU Int 2011;107:1216–22.